Newron Pharmaceuticals, a public company focused on novel Central Nervous System (CNS) and pain therapies, announces that it has completed a capital increase of approximately €23.2M (CHF24.3 million). This fundraising will be used to accelerate the development of Newron’s pipeline of innovative CNS therapeutics:
The company priority seems to be on NW-3509, an add-on therapy for schizophrenia, for which Newron plans to start a Phase II study in Q3 2015. NW-3509 modulates neuronal hyper-excitability and has shown activity in vivo in a broad range of psychosis, mania, anxiety, cognition and depression animal models. NW-3509, acting by a different mechanism from current antipsychotics, has not only the potential to address unmet medical needs regarding schizophrenia, but also to treat Bipolar Disorders without inducing sedation. On 15th January 2015, Newron announced the completion of the first in man US Phase I study. NW-3509 was well-tolerated at all doses.
The flagship compound of Newron is Xadago (safinamide). Safinamide is a Parkinson disease add-on therapy to both dopamine agonists and levodopa,